Reactions 1680, p230 - 2 Dec 2017 Acute cerebellar ataxia: case report A 56-year-old man developed acute cerebellar ataxia during treatment with metronidazole [duration of treatment to reaction onset not stated]. The man presented with complaint of progressive imbalance while walking. His history was significant for swaying side to side, vitiligo and megaloblastic anaemia due to vitamin B12 deficiency. He was receiving regular vitamin B12 injections. Investigations revealed gait and truncal ataxia. MRI results revealed bilaterally symmetrical T2 and FLAIR hyperintensity in dorsal pons and dentate nucleus. Further analysis of his history revealed that, he was on oral metronidazole 400mg three times/day from the past two weeks for loose motions. Consequently, a diagnosis of metronidazole induced acute cerebellar ataxia was considered based on his test results. The man was hospitalised, and metronidazole was discontinued. Subsequently, his symptoms resolved within seven days. During follow up examination at one month, he was asymptomatic. Author comment: "A diagnosis of metronidazole-induced acute cerebellar ataxia was made in the presence of the clinical features on neuroimaging findings and temporal relationship with metronidazole use." Duberkar D, et al. 56-Year-Old Male With Acute-Onset Ataxia After Metronidazole Use and a Typical MRI Appearance. Movement Disorders Clinical Practice 2: 422-423, No. 4, Dec 2015. Available from: URL: http:// doi.org/10.1002/mdc3.12186 - India 803284579 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud